C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients
treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form
(rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the
immunological profile following single and repeated treatment with Ruconest.
Details
Lead Sponsor:
Pharming Technologies B.V.
Treatments:
Complement C1 Inactivator Proteins Complement C1 Inhibitor Protein